ABBV vs MRVL: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Marvell Technology, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Marvell Technology, Inc. · Technology
$133.37
+23.0% upside to fair value
High Conviction
Grade B
QuantHub Verdict
MRVL has more upside to fair value
(+23.0%).
MRVL trades at a lower forward P/E
(42.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MRVL |
| Current Price |
$197.69 |
$133.37 |
| Fair Value Estimate |
$210.22 |
$164.02 |
| Upside to Fair Value |
+6.3%
|
+23.0%
|
| Market Cap |
$349.7B |
$116.6B |
| Forward P/E |
83.3x
|
42.4x
|
| EV / EBITDA |
23.4x
|
—
|
| Price / Sales |
5.7x
|
14.2x
|
| Price / FCF |
18.7x
|
83.7x
|
| Revenue Growth YoY |
+10.0%
|
+7.0%
|
| Gross Margin |
70.2%
|
50.1%
|
| Operating Margin |
26.7%
|
16.3%
|
| Return on Equity |
-361.6%
|
19.4%
|
| Dividend Yield |
0% |
— |
| FCF Yield |
5.35%
|
1.2%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Marvell Technology designs semiconductors for data infrastructure, including storage, networking, connectivity for AI, cloud, 5G, and automotive; the business excels with a dominant Data Center segment driving 42% FY2026 revenue growth to $8.2B amid AI demand, strong leadership under long-tenured CEO Matt Murphy, and robust 50% gross margins, though offset by earnings decline and non-Data Center …
Accumulation Zones
| Metric |
ABBV |
MRVL |
| Zone Low |
$157.66 |
$123.02 |
| Zone High |
$178.69 |
$139.42 |
| In Buy Zone? |
No
|
Yes
|